SGLT2 inhibitors beat sulfonylureas in reducing mortality: study
The real-world data also finds a survival benefit in staying on metformin and adding an SGLT2 inhibitor rather than using gliflozin monotherapy
Patients with type 2 diabetes treated with metformin have a better chance of living longer if they add an SGLT2 inhibitor rather than a sulfonylurea as second-line therapy, a large cohort study shows.
Furthermore, the combination of metformin and an SGLT2 inhibitor reduces all-cause mortality by 30% compared with SGLT2 treatment alone.
